US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye: Idogen - Could be in for a long period of uncertainty

Idogen has suffered a setback in their pre-clinical work, requiring more evaluation and thus delays in the timelines. The uncertainty has increased significantly and we are adjusting our expectations, arriving at a new fair value range.  Read more and download research update: http://bit.ly/2tcMwWU  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.

Redeye: Idogen - Preparations and capital raise on the agenda

Idogen continues the preparations to get their IDO projects into clinic. To finance the push, a SEK 60 million equity raise has been announced. With this report we provide an update on our take on the case. Read more and download research update: http://bit.ly/2SEftX8 Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Redeye: Idogen - Trying to modify mother nature

We are initiating coverage of Idogen, a Swedish early-stage biotech play focused on developing cell therapies. The concept could be used to treat patients by modifying their own immune system and has an attractive commercial potential. But it is still in the very early stages of development and many critical steps remain, hence, the risk level is high. Read more and download the initial analysis: https://goo.gl/axSdLF Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered

There are no items matching the current filter
There are no more items matching the current filter
Back to top